Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ocular surface inflammation refers to a pathological inflammatory response affecting the tissues that make up the ocular surface, including the cornea, conjunctiva, limbus, eyelids (including meibomian glands), and associated structures such as the lacrimal gland. This inflammation disrupts normal ocular surface homeostasis and is a central feature in various diseases collectively termed Ocular Surface Inflammatory Disorders (OSID).
Drugs aim to reduce leukocyte infiltration, suppress pro-inflammatory cytokine release, and restore ocular surface homeostasis through immunosuppression, lubrication, or management of contributing factors like lid hygiene.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular Surface Inflammation (OSI).